Prevalence and clinical correlates of substance use disorders in South African Xhosa patients with schizophrenia - PubMed

Purpose: To determine the prevalence of substance use disorders (SUDs) in patients with schizophrenia in a sample from South Africa and compare the clinical and demographic correlates in those with and without co-occurring SUDs.

Methods: Patients with schizophrenia were interviewed using the Xhosa version SCID-I for DSM-IV. We used logistic regression to determine the predictors of SUDs.

Results: In the total sample of 1420 participants, SUDs occurred in 47.8%, with the most prevalent SUD being cannabis use disorders (39.6%), followed by alcohol (20.5%), methaqualone (6.2%), methamphetamine (4.8%) and other SUDs (cocaine, ecstasy, opioids, 0.6%). Polydrug use occurred in 40%, abuse occurred in 13.5%, and 39.6% had at least one substance dependence diagnosis. Significant predictors of any SUD were younger age (41-55 vs. 21-30: OR = 0.7, 95% CI = 0.5-0.9), male sex (OR = 8.6, 95% CI = 5.1-14.6), inpatient status (OR = 1.7, 95% CI = 1.3-2.1), post-traumatic stress symptoms (OR = 4.6, 95% CI = 1.6-13.3), legal (OR = 3.4, 95% CI = 2.0-5.5) and economic problems (OR = 1.4, 95% CI = 1.0-2.0). Methamphetamine use disorders occurred significantly less often in the Eastern compared to the Western Cape provinces. Inpatient status and higher levels of prior admissions were significantly associated with cannabis and methamphetamine use disorders. Post-traumatic stress symptoms were significantly associated with alcohol use disorders. Anxiety disorders were associated with other SUDs.

Conclusion: SUDs occurred in almost half of the sample. It is important for clinicians to identify the presence of SUDs as their presence is associated with characteristics, such as male sex, younger age, inpatient status, more prior hospitalisations, legal and economic problems, PTSD symptoms and anxiety.

Conflicts of interest

HT, ES, SM, MC, and GS and have not received any financial or commercial related compensation that can be considered to represent a conflict of interest. DJS is supported by the Medical Research Council of South Africa and has received research grants and/or consultancy honoraria from: Abbott, Astrazeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda, Tikvah, and Wyeth. D.J.S. is also on the scientific advisory board of the TLC Foundation for Body-Focused Repetitive Behaviours, the Anxiety and Depression Association of America (ADAA), and the South African Depression and Anxiety Support Group. SM has received incentive funding for rated researchers from the South African National Research Foundation (NRF) (grant number 119375)

1. 1. Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG (2005) The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 112 (2):141–148. doi:10.1111/j.1600-0447.2005.00554.x - DOI - PubMed
2. 1. Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G (2007) Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. JClinPsychiatry 68 (5):767–774 - PubMed
3. 1. Cantor-Graae E, Nordstrom LG, McNeil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia research 48 (1):69–82 - PubMed
4. 1. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2009) Prevalence of alcohol use disorders in schizophrenia--a systematic review and meta-analysis. Acta Psychiatr Scand 120 (2):85–96. doi:10.1111/j.1600-0447.2009.01385.x - DOI - PubMed
5. 1. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia bulletin 36 (6):1115–1130. doi:10.1093/schbul/sbp031 - DOI - PMC - PubMed